EUNCL is providing a comprehensive set of characterisation tests
European Nanomedicine Characterization Laboratory (EUNCL) has access to a comprehensive set of characterization tools and assay systems to analyse physical, chemical, in-vitro and in-vivo biological properties allowing researchers in academia, industry and government to translate their nanoproducts towards clinical evaluation more rapidly and for lower cost. The aim is to reduce the development risks and eliminate Med-NPs unfit for clinical use at an early stage.
The EUNCL will offer a comprehensive portfolio of assays (Assay Cascade) that will allow the full characterization of the nanoparticles' physico-chemicals attributes, their in vitro biological properties, and their in vivo compatibility using animal models in a constant quality controlled environment.
After quality pre-check and in adequacy with the nanoparticle type and expected objective, the EUNCL provides an appropriate set of assays through a dedicated and tired characterization plan.
Proposed nanotechnology materials and strategies submitted to the EUNCL are evaluated according to their projected impact on clinical applications. If a nanotechnology /material is selected for characterization, the EUNCL's services are provided at no cost to the submitting investigator.
The primary outcome of the EUNCL assay cascade is the collection of data on the nanoparticles' characteristics and their interaction and compatibility with biological systems (in-vitro and in-vivo). This data is provided to the sponsor through a report to support a CTA application and subsequent clinical trials.
European Nanomedicine Characterisation Laboratory (EUNCL)